Ms Lauren Wilson

(United States of America)

Follow

Contributor content

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

Presentation

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

ESC 365 is supported by

novartis

Explore sponsored resources